homepage-top-section

The approval is intended for adults with PsA who have had inadequate response or intolerance to previous disease-modifying antirheumatic drug (DMARD) therapy. Sotyktu can be used alone or

The acquisition has been approved unanimously by both companies’ boards of directors, with the transaction expected to close in the third quarter of 2026. Angelini Pharma will purchase

Oruka has licensed the Halozyme technology for use with its lead programme, ORKA-001, which is in development to treat psoriasis and related inflammatory conditions, and up to one

Following a successful tender offer and subsequent merger, the companies announced the completion of the transaction, making Terns a wholly owned subsidiary of MSD. The US Food and

The financing includes a $43m extension led by 8VC, with participation from existing investors BioAdvance, Benjamin Franklin Technology Partners, DCVC Bio, Gaingels, Hatch BioFund and Modi Ventures. New

The Ozempic oral pill, approved by the Food and Drug Administration (FDA), offers an option for adults with type 2 diabetes to manage blood sugar and cardiovascular risk

The acquisition aims to strengthen LEO Pharma’s capabilities while leveraging Replay’s high payload herpes simplex virus (HSV) delivery vector. It is set to expand LEO Pharma’s pipeline in

On a non-GAAP basis, net income rose 12% to $1.04bn from $928m. GAAP diluted earnings per share (EPS) stood at $6.75 while non-GAAP diluted EPS grew 15% year-on-year

The PRV was awarded after the US Food and Drug Administration (FDA) granted accelerated approval for the Kresladi (marnetegragene autotemcel) gene therapy. Kresladi comprises the patient’s own haematopoietic stem cells that